Judith Greciet on Targeting Iron Dysregulation: PulseSight’s Next-Generation Approach to Geographic Atrophy

Shots: PulseSight Therapeutics is advancing a novel approach to Geographic Atrophy (GA) with PST-611, a first-in-class non-viral gene therapy designed to restore iron homeostasis by targeting transferrin biology—an upstream driver of retinal degeneration. At ARVO 2026, PST-611 delivered encouraging Phase I results, demonstrating an excellent safety and tolerability profile, stable visual acuity, and early signals of potential functional…

BySaurabh Chaubey2 days ago

EVENTS

London Biotechnology Show 2026 | 18-19 November | Excel London

Get ready to connect with the innovators, investors, and industry leaders shaping the future of biotechnology at the London Biotechnology Show 2026. Taking place alongside London Life Sciences Week, the event is set to become one of the UK’s most influential gatherings for the global biotech and life sciences ecosystem. Bringing together 4,000+ attendees and…

BySaurabh ChaubeyJune 12, 2026

VIEWPOINTS

Dr. Orla Cloak on Manufacturing Excellence: Minaris Vision for Advanced Therapies

Shots: Minaris is advancing its dual-business strategy through specialized Advanced Therapies and Advanced Testing units, enabling sponsors to streamline development, manufacturing, biosafety testing, and commercialization within one integrated global organization. Minaris is focused on solving key cell & gene therapy manufacturing challenges by reducing variability, accelerating tech transfer, improving “first time right” execution, and lowering…

BySaurabh ChaubeyMay 18, 2026

MAGAZINE

PharmaShots Magazine-May-2026 Edition

Shots: PharmaShots’ May Edition explores how AI is transforming commercial strategies across the healthcare ecosystem by enabling predictive analytics, personalized engagement, dynamic launch planning, and real-time omnichannel optimization while balancing compliance and measurable ROI. The magazine highlights key industry movements shaping global biopharma, including AI-driven drug discovery collaborations, strategic M&A activity, advancements in cell and…

ByAditya SinghMay 14, 2026

NEWS

LEO Pharma to Acquire Replay for Rare Skin Disease Gene Therapy Platform

Shots: LEO Pharma has entered into a definitive agreement to acquire Replay, expanding its dermatology pipeline with Replay’s herpes simplex virus-based gene therapy platform for rare genetic skin disorders As per the deal, LEO will acquire Replay for $50M upfront, plus milestone payments & tiered single-digit royalties, while adding Replay’s HSV design and manufacturing expertise…

ByRidhi RastogiMay 1, 2026

NEWS

Novartis’ Itvisma Receives the CHMP Positive Opinion for Spinal Muscular Atrophy

Shots: The CHMP has recommended Novartis' Itvisma (onasemnogene abeparvovec) for the treatment of pts (≥2yrs.) living with 5q spinal muscular atrophy (SMA) harboring a confirmed bi-allelic mutation in the SMN1 gene Opinion was based on the P-III (STEER) trial & P-IIIb (STRENGTH) study, where STEER showed a 2.39-point improvement in the HFMSE with effects sustained…

ByRidhi RastogiApril 27, 2026

NEWS

Regeneron Reports the US FDA Accelerated Approval of Otarmeni (lunsotogene parvec-cwha) in Genetic Hearing Loss

Shots: Otarmeni was approved under CNPV for pediatric & adult pts with sev. to profound and profound sensorineural hearing loss due to biallelic OTOF gene variants, with preserved outer hair cell function & no prior cochlear implant. It will be provided free of charge in the US by Regeneron Approval was based on the P-I/II…

ByRidhi RastogiApril 24, 2026

NEWS

Eli Lilly to Acquire Kelonia Therapeutics for ~$7B

Shots: Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics, expanding Lilly’s genetic medicine capabilities As per the deal, Lilly will acquire Kelonia for ~$7B in cash, incl. $3.25B upfront, & additional clinical, regulatory & commercial milestone payments; closing expected in H2’26 Acquisition will add Kelonia’s in vivo gene placement system (iGPS0) & its lead asset, KLN-1010, a one-time IV…

ByRidhi RastogiApril 21, 2026

NEWS

Ultragenyx Reports the P-III (Enh3ance) Trial for DTX301 AAV8 Gene Therapy in OTC Deficiency

Shots: Ultragenyx has reported the P-III (Enh3ance) study data assessing DTX301 AAV8 gene therapy vs PBO for the treatment of ornithine transcarbamylase (OTC) deficiency DTX301 reduced 24hr. plasma ammonia by 18% vs PBO at Wk. 36, with ammonia levels maintained in the normal range, despite a 27% mean decrease in scavenger drugs & ~13% increase…

ByRidhi RastogiMarch 13, 2026

NEWS

Ocugen Reports Positive Preliminary P-II (ArMaDa) Data of OCU410 in Geographic Atrophy (GA) Secondary to Dry AMD

Shots: Ocugen has reported preliminary 12mos. data from its P-II (ArMaDa) trial (n=51) of OCU410 (AAV5-RORA) in GA secondary to dry AMD, with ~50% of pts evaluated to date Trial showed a 46% reduction in GA lesion growth vs control (medium + high dose), with the medium dose achieving a 54% reduction; 50% pts achieved…

ByRidhi RastogiJanuary 16, 2026

London Biotechnology Show 2026 | 18-19 November | Excel London

Dr. Orla Cloak on Manufacturing Excellence: Minaris Vision for Advanced Therapies

PharmaShots Magazine-May-2026 Edition

LEO Pharma to Acquire Replay for Rare Skin Disease Gene Therapy Platform

Novartis’ Itvisma Receives the CHMP Positive Opinion for Spinal Muscular Atrophy

Regeneron Reports the US FDA Accelerated Approval of Otarmeni (lunsotogene parvec-cwha) in Genetic Hearing Loss

Eli Lilly to Acquire Kelonia Therapeutics for ~$7B

Ultragenyx Reports the P-III (Enh3ance) Trial for DTX301 AAV8 Gene Therapy in OTC Deficiency

Ocugen Reports Positive Preliminary P-II (ArMaDa) Data of OCU410 in Geographic Atrophy (GA) Secondary to Dry AMD

Contact US

FOLLOW US